Saxena, A
This limited coverage can be attributed to the prevailing perception of obesity as primarily an aesthetic concern rather than a medical condition
Related resources: Kisspeptin Profile Weight Loss Peptide Dosage Comparison Chart (2026) The three GLP-1 track peptides produce dramatically different weight loss outcomes
[DOI] [PubMed] [Google Scholar] 8.Li T., Zhao J., Cao H., Han X., Lu Y., Jiang F., Li X., Sun J., Zhou S., Sun Z., et al
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers